PATIENTS

For us, it’s personal. At Imago, we are committed to finding new ways to treat myeloproliferative neoplasms – diseases which pose great challenges to patients, their families and treating physicians. We are dedicated to focusing on areas of serious clinical need, where our unique insights into the relationship between normal blood cell development and disease can be translated into new treatments for serious or life-threatening diseases. Our team is made up of seasoned scientists, physicians and life science professionals who see promise for patients through the lens of science.

Active Clinical Trials

Essential Thrombocythemia

Part of the MPN family, essential thrombocythemia (ET) is a rare blood cancer that results in the overproduction of platelets, which increases the risk of blood clots and bleeding. The disease impacts between 80,000 – 100,000 people in the U.S., and average survival for newly diagnosed patients is approximately 18 years. There remains a significant unmet need for new ET medicines that can effectively reduce patient platelet levels without general bone marrow suppression while slowing the progression of the underlying disease.

We are evaluating bomedemstat for the treatment in patients with ET. By working to address the primary clinical feature of ET, elevated platelets, bomedemstat has the potential to become the standard of care for patients with ET who are intolerant or resistant to hydroxyurea, the mainstay of treatment for this disease. For more information on our ongoing Phase 2 clinical trial, visit our website or clinicaltrials.gov, and learn about an investigator initiated trial with bomedemstat in essential thrombocythemia at clinicaltrials.gov.

Clinical Trial Website

Myelofibrosis

Myelofibrosis (MF) is a progressive cancer in which the bone marrow (the spongy tissue inside bones that helps blood cells grow) is gradually replaced by fibrous, scar-like tissue. This scarring process slowly reduces the marrow’s ability to make blood cells. As a result, the body cannot make enough of the cells that fight infection (white blood cells), carry oxygen (red blood cells) and help clot blood (platelets). Not having enough of these cells can result in anemia (leaving patients feeling weak or tired), infections and bleeding.

As the disease progresses, the body attempts to make blood cells outside the bone marrow, notably in organs such as the spleen and liver, which slowly become enlarged. There are over 50,000 patients with MF in the U.S., E.U. and Japan, many of which have a poor quality of life owing to chronic fatigue, anemia, pain, itching, fever and night sweats. Median survival post-diagnosis is approximately 5 years.

There remains a high unmet need for alternative disease-modifying therapies that improve symptom management. We are evaluating bomedemstat for treatment in patient with myelofibrosis, which has the potential to be a differentiated, first-in-class, disease-modifying therapy for a patient population with very limited therapeutic options. For more information on our Phase 2 clinical trial, visit our clinical study website or clinicaltrials.gov.

Video: Five Important Things to Know About Bomedemstat for Myelofibrosis Treatment

Clinical Trial Website

Polycythemia Vera

Bomedemstat may prove to be a treatment for polycythemia vera (PV), an MPN characterized by the excessive production of red blood cells. The prevalence in the U.S. is approximately 100,000 patients and there is currently no curative treatment. Low-risk patients are typically managed initially with phlebotomy and higher-risk patients are typically prescribed hydroxy urea or a cytotoxic therapy, like hydroxyurea. Because LSD1 inhibition modulates the proliferation of malignant blood cells, bomedemstat may represent a novel therapeutic option for this patient population. An ongoing investigator-sponsored trial is evaluating bomedemstat in PV patients who have failed at least one standard therapy.

For more information about our investigator-sponsored trial investigating bomedemstat for PV, visit clinicaltrials.gov.